Scientists have shown how a protein responsible for adapting to low oxygen conditions (hypoxia), causes increased expression of fetal hemoglobin (HbF) in adults. The finding has implications for treating sickle cell disease and beta-thalassemia, serious blood disorders that affect millions of individuals. The research was published in Nature.
Hemoglobin is like a protein sponge that soaks up oxygen and allows red blood cells to ferry it throughout the body. Adult hemoglobin contains four protein subunits – two beta-globin and two alpha-globin. Mutations in beta-globin cause sickle cell disease and beta-thalassemia. But humans have another hemoglobin subunit gene (gamma-globin), which is expressed instead of beta-globin during fetal development. Gamma-globin combines with alpha-globin to form HbF. Normally around birth, gamma-globin expression is turned off and beta-globin is turned on, resulting in a switch from HbF to adult hemoglobin.
“We have known for many years that persistent HbF expression after birth can alleviate the symptoms of sickle cell disease and beta-thalassemia,” said corresponding author. “And very high HbF levels can cure these diseases, despite the defective beta-globin genes being present. Therefore, many laboratories are focused on understanding the perinatal switch from gamma- to beta-globin gene expression and figuring out new ways to reverse it with drugs or genetic therapies.”
The group discovered that hypoxia inducible factor 1 (HIF1) directly promotes transcription of the gamma-globin gene to enhance HbF production. HIF1 is an important component of cells’ ability to sense and adapt to hypoxic conditions. In low oxygen conditions, HIF1 accumulates in many tissues and activates hundreds of genes, including HbF in red blood cells.
First author showed that a drug that activates part of the cellular hypoxia response inhibits sickling of red blood cells derived from adults with sickle cell disease. The drug, a proline hydroxylase inhibitor, caused HIF1 to accumulate, bind a DNA regulatory region near the gamma globin gene, activating its transcription to produce HbF and inhibit cell ‘sickling.’ Proline hydroxylase inhibitors are currently in late stage clinical development for the treatment of anemia associated with chronic kidney disease. These drugs work by stabilizing HIF proteins to stimulate the production of erythropoietin, a hormone that drives red blood cell production.
“Our findings indicate that proline hydroxylase inhibitors might be useful for treatment of sickle cell disease or beta-thalassemia, where turning on HbF production has therapeutic benefits,” the senior author said. “Approximately 20% of adult sickle cell disease patients develop kidney failure with related anemia. Proline hydroxylase inhibitors might serve a dual purpose in these individuals, by stimulating the production of both erythropoietin and HbF.”
The Nobel Prize in Physiology or Medicine was awarded to the discovery of the HIF pathway in 2019. The current study, led by the group, establishes a direct connection between this hypoxia adaptation and HbF expression. This connection explains longstanding clinical observations that HbF is induced during accelerated production of red blood cells after exposure to hypoxia or in some forms of anemia, conditions termed “stress erythropoiesis.”
“Identification of gamma-globin as a HIF target gene supports the notion that HbF evolved as a protective mechanism against hypoxia,” the author said. “Studies of hemoglobin over more than 50 years have established many general principles in biology and medicine. It is exciting and gratifying that investigations into hemoglobin and globin gene expression continue to produce new, clinically relevant discoveries.”
https://www.nature.com/articles/s41586-022-05312-w
A link between hypoxia and fetal hemoglobin production
- 683 views
- Added
Latest News
Propionic acid protects ner…
By newseditor
Posted 28 Jan
How cells prevent harmful e…
By newseditor
Posted 28 Jan
Structured cerebellar conne…
By newseditor
Posted 28 Jan
Origins of pleasurable touc…
By newseditor
Posted 25 Jan
Unknown way cells protect t…
By newseditor
Posted 25 Jan
Other Top Stories
Mating can cause epigenetic changes that last for 300 generations
Read more
Gene therapy to treat developmental disabilities
Read more
Neurotransmitter release impairment in schizophrenia with genetic m…
Read more
Prenatal editing in preclinical model to correct lysosomal storage…
Read more
Potential role of 'junk DNA' sequence in aging, cancer
Read more
Protocols
Machine learning prediction…
By newseditor
Posted 09 Jan
Differentiating PC12 cells…
By newseditor
Posted 09 Jan
Ultrasensitive sensors reve…
By newseditor
Posted 05 Jan
In vitro-derived medium spi…
By newseditor
Posted 04 Jan
Molecular and spatial signa…
By newseditor
Posted 30 Dec
Publications
Brainstem networks construc…
By newseditor
Posted 28 Jan
The role of platelets in im…
By newseditor
Posted 28 Jan
Invariant inhibition to cal…
By newseditor
Posted 27 Jan
Birdsong neuroscience and t…
By newseditor
Posted 27 Jan
Touch neurons underlying do…
By newseditor
Posted 25 Jan
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 10 Mar
ASCO-2020-GYNECOLOGIC CANCER
By newseditor
Posted 10 Mar